Allogeneic hematopoietic cell transplantation (HCT) offers the chance of cure for patients with non-transformed follicular lymphoma (FL), but is associated with the risk of non-relapse mortality (NRM). The aim of this study was to identify subgroups of FL patients who benefit from HCT. The European Society for Blood and Marrow Transplantation (EBMT) Minimum-Essential-A Data of 146 consecutive patients who received HCT for FL between 1998 and 2008 were extracted from the database of the German Registry 'DRST'. Diagnosis of FL was verified by contact with the reference pathologists. Estimated 1-, 2-and 5-year overall survivals (OS) were 67%, 60% and 53%, respectively. Day 100 NRM was 15%. Thirteen out of 33 patients (40%) with treatment-refractory disease (RD) at the time of transplantation survived long term. Univariate statistical analysis suggested limited chronic GvHD, donor age ⩽ 42 years and TBI-based conditioning in treatment refractory patients to correlate with favorable OS. Independent prognostic factors for OS were treatmentsensitive disease and limited chronic GvHD for the whole cohort, and additionally TBI-based conditioning for the treatment refractory subgroup. In contrast, patient age ⩾ 55 years had no impact on outcome. Thus, HCT for FL is associated with acceptable NRM, and offers a substantial chance of cure for patients with RD or advanced age. Donors ⩽ 42 years should be preferred if available.
INTRODUCTION
Non-transformed follicular lymphoma (FL), a mature B-cell neoplasm, is the second most common subtype of malignant lymphoma in adults (~20-25%). 1 Conventional treatment options for FL patients include multiagent chemotherapy combined with anti-CD20 monoclonal Abs 2, 3 or radioimmunotherapy, 4, 5 leading to an improvement of median overall survival (OS) of 12-14 years in the last decade. 6 High-dose salvage regimens, including chemotherapy, rituximab and/or TBI, followed by autologous hematopoietic cell transplantation (HCT) have also clearly improved 5-year PFS and OS. [7] [8] [9] More recently, the type II CD20-Ab obinutuzumab, 10, 11 bortezomib, 12 lenalidomide, 13 idelalisib, 14 ibrutinib, 15 bcl-2 inhibitors 16 and Car T cells 17 have potential for further refinement of the clinical outcome in FL patients. However, despite all recent innovative approaches, cure of FL cannot yet be achieved. Thus, the clinical course of FL remains to be characterized by a series of subsequent relapses accompanied by an increase of cumulative drug toxicity and finally by a treatment refractory state, resulting in progressive disease (PD). Since the 1990s, there has been increasing interest in evaluating the role of allogeneic HCT to cure patients with advanced FL by its potential to induce an allo-immune reaction named graft versus lymphoma (GvL) effect. 18, 19 In the first published series of HCT for patients with FL myeloablative conditioning protocols (MAC) were used. [20] [21] [22] These studies demonstrated that allogeneic HCT has the potential for cure of relapsed/chemotherapy-resistant FL. However, owing to the high non-relapse mortality (NRM) rate of up to 40% this treatment modality had to be limited to patients o50 years and a Karnofsky performance status ⩾ 90%. 23 To extend the use of HCT to patients with advanced age and comorbidities, reduced intensity conditioning (RIC) protocols were developed and became increasingly popular during the last decade. The results of several, but not all clinical trials show low NRM and high OS, and event-free survival (EFS) rates after RIC as compared with MAC in FL. [24] [25] [26] [27] [28] [29] [30] [31] The present retrospective study enrolled a large cohort of intensively pretreated patients who received HCT for nontransformed histological grades 1-3A FL. The aim of the study was to identify prognostic factors for transplantation outcome, that is, to define subgroups of FL patients who will or will not benefit from transplantation.
PATIENTS AND METHODS

Patient enrollment
The DRST (German Registry for Stem Cell Transplantation) database was screened for patients who had received HCT for non-Hodgkin lymphoma (NHL) between 1998 and 2008. A total of 1342 patients were identified. All patients transplanted for lymphomas with a diagnosis other than FL, according to the current World Health Organization Classification of Tumours of Haematopoietic and Lymphatic Tissues (4th edition, 2008), were excluded if an unequivocal translation of formerly used nomenclatures to the World Health Organization classification was available. The remaining n = 226 patients were accepted as study candidates.
For these patients, local as well as pathologists of the National NHL Reference Panel were contacted in order to review the histological diagnosis according to the WHO classification. As a result, 80 study candidates were excluded from the analysis (n = 15: diffuse large B-cell lymphoma, n = 33: transformed FL, n = 6: FL grade 3B, n = 26: indolent lymphomas other than FL, such as mucosa associated lymphoid tissue lymphoma, chronic lymphocytic leukemia, marginal zone lymphoma and mantle cell lymphoma). Of note, no patient was identified among the study candidates who proved to have FL on review only. Thus, a total of n = 146 patients with the definite diagnosis of non-transformed FL (histological grades 1-3A) could finally be enrolled in this study. Table 1 shows relevant baseline characteristics and HCT clinical data of 146 qualified patients. All available MED-A data were extracted from the DRST database-irrespective of whether the EBMT data format 31/07/2007 or former versions had been used.
Local data DRST managers were asked to provide additional patient and donor data (relevant to this study), which were not covered by the available MED-A formats, for example: (1) detailed data on conditioning regimens (name and cumulative dosages of applied drugs, irradiation dose in the case of TBI) and (2) evidence for the response to treatment (sensitive/refractory) at the time of HCT (results of computed tomography or positron emission tomography scans and biopsies).
As data entry of chronic GvHD stages remains difficult even for experienced data managers, data source verification was performed by the medical directors of the transplant units in person according to the grading system proposed by the Seattle group. 32 The data access committee of the German Registry has formally approved this non-interventional retrospective study. The informed consent of all patients with entries in the DRST database has been provided by all cooperating centers.
Evaluation of engraftment
The day of engraftment was defined as the first of three consecutive days post transplantation with a neutrophil count of 4500/μl. Patients with no evidence of engraftment who did not survive to day 28 post transplantation were excluded from the engraftment analysis.
Definition of myeloablative, reduced intensity and non-myeloablative conditioning
The authors decided to consider the proposal of Bacigalupo et al. in order to assign a given conditioning regimen to belong to either of three defined groups, named MAC, RIC and non-myeloablative conditioning (NMAC). MAC-for example, protocols containing TBI ⩾ 5 Gy (single dose) or ⩾ 8 Gy (fractionated dose), or busulfan 48 mg/kg body weight (BW) p.o. or IV equivalent-causes irreversible cytopenia requiring stem cell support. In contrast, NMAC regimens-for example, TBI ⩽ 2 Gy ± purine analog-can be applied without stem cell support. RIC-for example, protocols containing reduced dose (at least 30%) of alkylating agents or TBI such as combinations of fludarabine ± alkylating agent/TBI-do not meet the criteria for MAC and NMAC. However, even if cytopenia after RIC is variable, stem cell support is generally recommended. 33 Evaluation of response-to-treatment state at the time of HCT Response to prior treatment was assessed using the criteria of the international working group. Treatment-sensitive disease was defined as first or subsequent CR or PR of all sites of disease without occurrence of new lesions after completion of the recently applied treatment modality (chemotherapy ± antibodies ± local irradiation ± autologous HCT (chemotherapy ± TBI)).
Treatment-refractory disease (RD) was defined as a disease status in patients, who did not achieve a PR or showed PD after conventional treatment options ± autologous HCT.
Evaluation of disease response to HCT Best disease status after HCT was evaluated for all patients surviving day 30 using the criteria of the International Working Group (CR continued, CR achieved, PR and RD).
Relapse after HCT was defined as recurrence of FL in patients who were in CR at the time of transplantation or had achieved CR after HCT.
PD was defined as an increase of persistent lymphoma mass or development of new areas of the disease not previously evident in patients without CR before and after the transplantation.
Early death
Early death post HCT was defined as the demise of the patient before day 30 post transplantation.
HLA typing of donors and recipients
HLA typing of unrelated donors and recipients was performed by high-resolution molecular typing of the HLA loci A, B, C, DRB1 and DQB1 as described previously. 35 In the related setting, low-resolution molecular HLA-A, B and DRB1 of donors and recipients were accepted if results could be confirmed by the segregation analysis of HLA haplotypes (pedigree plot analysis).
Statistical analysis
Statistical analysis was performed using MEDAS IT software (C Grund, EDV Systems, Margetshoechheim, Germany). Primary end points for analysis of HCT outcome were OS, EFS and NRM. For the evaluation of all aspects of chronic GvHD patients not surviving to day 100 post HCT were censored. Definitions used: OS was the number of days after HCT to eventually death from any cause. EFS was the time interval from the date of HCT to the date of relapse/progression of FL or death from any cause. NRM was the time to death of any cause without documented prior relapse/progression of FL. All clinical baseline parameters, as depicted in Table 1 , were suspected to be risk factors for HCT outcome, and therefore submitted to statistical analysis for their impact on OS, EFS and NRM, as was the clinical time dependent outcome parameter of chronic GvHD. The analysis of the impact of all considered baseline and outcome variables for OS, EFS and NRM were evaluated using univariate statistical analysis (Kaplan-Meier log-normal approximation, log-rank test and U-test), followed by multivariate statistical analysis using established Cox regression models evaluating changes in treatment or prognostic status (time dependent covariates).
36,37
RESULTS
Baseline characteristics of study transplantations
The baseline characteristics of the n = 146 study patients are depicted in Table 1 .
Pre-treatment Before allogeneic HCT, all study patients were intensively pretreated with multiple regimens of chemotherapy ± rituximab (median: 3, range 1-10). Thirty study patients received localized radiotherapy at various time points of their disease course. Twenty-four patients received 12 Gy TBI-containing conditioning regimen in preparation for an autologous HCT. In all patients treated with localized radiation and/or additional TBI, the cumulative dosage of radiotherapy did not exceed a cumulative dosage of 40 Gy. Thus, for all enrolled patients, a TBI-containing conditioning regimen for allogeneic HCT of/or exceeding 4 Gy was retrospectively regarded to be feasible. Before allogeneic HCT 90/146 patients (62%) had undergone autologous HCT either after high-dose chemotherapy alone (n = 66) or a TBI-containing conditioning regimen (n = 24).
Disease status at the time of HCT Despite all efforts, the precise disease status at the time of HCT (sensitive vs refractory) could not be defined in three patients. Thus, HCT outcome analysis focusing on remission status at the time of HCT was limited to a total of n = 143 patients (cf. Figures 1  and 2 ). At the time of HCT, 110 patients (77%) had sensitive disease, whereas 33 patients (23%) had RD.
Conditioning regimens
The distribution of the study patients receiving MAC, RIC or NMAC is detailed in Table 1 . N = 65 patients (45%) received TBIcontaining conditioning, N = 24 patients (37%) were treated with high dose (12 Gy: n = 17, 10 Gy: n = 2 and 8 Gy: n = 5) and 41 patients (63%) with low-dose (4 Gy: n = 11and 2 Gy: n = 30) TBI regimens. Of note, only 5 of these 65 patients (7%) had previously received a TBI-containing regimen (n = 4: 2 Gy and n = 1: 4 Gy) in preparation for autologous HCT. Donors Sixty-three percent (92/146) of the enrolled patients had a male and 37% (54/146) a female donor. A donor/recipient sex mismatch (female donor/male patient) was documented in 29/146 cases (20%). Sixty-five patients (45%) were transplanted from sibling donors (HLA identical: n = 62 and partially HLA mismatched: n = 3) and 81 patients (55%) from unrelated donors (fully HLA matched: n = 57 and partially HLA mismatched: n = 24). The mean donor age (± s.d.) of related donors was 45.1 years ( ± 11.8; range 22-69 years) and of unrelated donors 36.4 years ( ± 9.2; range 20-56 years). This difference in age between related and unrelated donors was highly significant (P = 0.0007).
Clinical outcome OS and EFS. The median follow-up of surviving patients was 9.1 years (range 3.6-15.7). The Kaplan-Meier estimates for OS 1, 2, 5 and 10 years after HCT (95% confidence interval) were 67% (63-71), 60% (56-64), 53% (49-58) and 48% (44) (45) (46) (47) (48) (49) (50) (51) (52) . The corresponding estimates for EFS were 63% (59-67), 53% (49-58), 47% (42-51) and 40% (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) . Stable plateaus for OS and EFS were reached at the 50% and 42% level, respectively (cf. Figures 3a and b) .
Engraftment. Eight patients not surviving to day 28 post HCT were excluded from analysis. Engraftment was achieved in 99% (137/138) of evaluable patients. The time median for neutrophil recovery was 14 days (range: 5-43). Secondary graft failure was documented in o2% (2/138) of the cases.
GvHD. A total of 36% of the recipients (n = 51/146) developed clinically relevant (grades II-IV) acute GvHD. Among the patients at risk/surviving day 100 post HCT (n = 123), limited chronic GvHD was observed in 30% (n = 37/123) and extended chronic GvHD in 31% (n = 38/123).
Best disease status after HCT. Eight patients died early after transplant and five patients suffered from fatal failure of multiple organs, which did not allow for the evaluation of disease status. Nevertheless, these patients remained included in our study as an intent-to-treat analysis was performed.
The best disease status after HCT was CR in 79% (116/146), PR in 10% (14/146) and PD in 2% (3/146). In detail, continued CR was documented in all patients (n = 36) transplanted in CR, whereas CR was achieved in 57/74 (85%) of the cases transplanted in PR and in 22/33 (67%) of the recipients transplanted for refractory FL.
Relapse. Overall, of the n = 116 patients with documented CR after HCT only n = 17 (15%) relapsed. Fifteen of these relapses occurred during the first 3 years after HCT (first year: n = 6; second year: n = 4; and third year: n = 5). Notably, only two late relapses (beyond year 3) were diagnosed among the 77 patients with a follow-up 45 years and occurred 5.1 and 9.1 years after HCT.
Eight out of 17 relapsed patients (47%) achieved a subsequent CR, which proved to be stable in all cases until the end of the period of this study (median follow-up: 76 months, range 61-139 months). Reinduction treatment included application of donor lymphocyte infusions, rituximab, bendamustine and/or localized radiotherapy.
NRM. Cumulative NRM rates as calculated at days 30, 100 and at 24 months post transplantation were 4%, 15% and 35%, respectively (Supplementary figure 1) .
Causes of death. None of the patients with PD (n = 8) after HCT survived 42 years. Six study patients who relapsed also died, despite intensive multimodal treatment, due to progressive disease (Supplementary figure 2) .
The remaining 65 casualties were due to NRM such as infectious complications/extensive GvHD (n = 40), acute GvHD (n = 7), cerebral bleeding (n = 2), myocardial infarction (n = 3), pneumothorax (n = 1), pneumonitis (n = 1), encephalitis (n = 1), leukoencephalopathy (n = 1) and secondary malignancies (n = 9; laryngeal carcinoma (n = 1), gastric cancer (n = 2); secondary AML (n = 1), bronchial carcinoma (n = 2), post-transplant-related lymphoproliferative disease (n = 1), malignant melanoma (n = 1), cancer of unknown origin (n = 1)), respectively.
Risk factors for HCT outcome
Results of univariate statistical analysis Patient age. Our uni-and multivariate statistical analysis included patient age as a continuous as well as a discrete variable (age median: 48 years, 55 years vs ⩾55 years). We found that age in general had no impact on outcome irrespective of which type of variable was employed in our analysis. OS results for patients o 55 (n = 108) and ⩾ 55 years (n = 38) are depicted in Figure 4a , as this cutoff is frequently used in clinical studies to separate younger from elderly patients. Donor age. Donor age was found to have an impact on HCT outcome. A donor age of ⩽ 42 years was found to be the best cutoff value for predicting a favorable OS (P = 0.0088, cf. Figure 4b ) and EFS (P = 0.0070). The median ages of the young and elderly donor groups were 34 (range: 21-42) and 51 (range 43-69) years, respectively. Furthermore, in the case of chronic GvHD, young donor age was found to be linked to limited and advanced donor age to extended disease (U-test: P = 0.06). The observed effect of donor age on HCT outcome and chronic GvHD could mainly be attributed to the unrelated donor transplant setting (unrelated donors: median age 36.4 ± 9.2 years, related donors: median age: 45.1 ± 11.8 years, P = 0.0007).
Response-to-treatment state at the time of HCT. If all study patients (n = 146) were included in the statistical analysis, results for OS and EFS did not differ significantly for patients with sensitive and RD as shown in Figures 1a and b . However, if statistical analysis was confined to the largest subgroup of study patients who had received chemotherapy-only based conditioning (n = 80), the treatment-sensitive cohort showed a trend towards better OS (P = 0.087) and EFS (P = 0.058) rates as compared with patients with RD.
The impact of TBI-containing conditioning protocols on HCT outcome for patients with sensitive and RD was analyzed by direct comparison with the corresponding subgroups of patients conditioned with chemotherapy alone.
For patients with sensitive disease, the type of conditioning was found to have no influence on OS (P = 0.59) and EFS (P = 0.48). In contrast, for patients with RD, TBI-containing conditioning regimens resulted in improved OS and EFS rates. As shown in Figures 2a and b , the corresponding 95% confidence interval of the two subcohorts did not overlap and the level of significance for superiority of TBI-containing conditioning was almost reached for OS (P = 0.061) and EFS (P = 0.070) despite the small number of refractory patients treated by TBI (n = 14).
Beside the baseline parameters listed in Table 1 , the influence of the outcome parameter chronic GvHD on OS and EFS was analyzed after stratification according to the degree of the disease, that is, absent, limited or extended.
Patients with chronic GvHD (irrespective of stage) had a lower risk of relapse, if transplanted in CR, and a higher chance to achieve CR, if transplanted in PR or with PD (no chronic GvHD: 19/48, chronic GvHD: 11/75, P = 0.0019, χ 2 test). Patients with limited chronic GvHD reached better OS and EFS rates compared with the two other study cohorts, whereas the outcome for patients with absent or extended disease was found to be similar as evidenced by log-rank tests (OS: limited vs absent: Results of multivariate statistical analysis. As detailed in Table 2 , chemo-sensitive disease at the time of transplantation, use of TBI-containing conditioning protocols for patients with RD, and the presence of limited chronic GvHD are independent prognostic factors for improved EFS and OS after HCT. In contrast, multivariate statistical analysis could not establish donor age as an independent risk factor for HCT outcome due to the above-mentioned association of young donor age and limited chronic GvHD.
DISCUSSION
This retrospective multicenter study enrolled n = 146 consecutive patients who underwent allogeneic HCT after intensive pretreatment (cf. Table 1 ). The aim of the study was to identify subgroups of FL patients who benefited from HCT.
Review of pathology and retrospective data source verification for all data on chronic GvHD were part of the study. As only 25% of the patients were in CR at the time of HCT, the median follow-up time of 9.1 years for surviving patients appears to be adequate for the purpose of our evaluation.
The main finding of this study is that HCT offers a substantial chance of cure for patients with non-transformed FL (cf. Figure 3) , irrespective of whether presenting with treatment-sensitive or RD. The curative potential of HCT for sensitive and refractory FL is suggested by the stable OS and EFS plateaus reached after transplantation (cf. Figures 1a and b) . The results reported for the chemorefractory group are better than those outlined in most other publications. 29, 38, 39 A possible explanation might be the higher percentage of patients treated by TBI-based conditioning.
Multivariate statistical analysis (cf. Table 2 ) revealed three parameters as independent risk factors for a beneficial OS and EFS: treatment-sensitive disease at the time of HCT, as suggested by numerous previous studies, 21, [29] [30] [31] 38, 40, 41, 39 use of a TBI-containing conditioning regimen in patients with RD and the occurrence of limited chronic GvHD.
Univariate statistical analysis of the entire study population could not reveal a significant difference in HCT outcome for patients with sensitive and RD despite the sparse overlap of the corresponding 95% confidence intervals for OS and EFS (cf. Figures 1a and b) . However, this analysis was confounded by the type of conditioning regimen used. If analysis was confined to study patients (n = 80) who received chemotherapy-only based conditioning, the subcohort of 61 patients with sensitive disease had better OS (P = 0.087) and EFS (P = 0.058) rates than the 19 patients with RD.
To evaluate the impact of TBI-containing conditioning on HCT outcome the above-mentioned two subcohorts were used as reference. In patients with sensitive disease, OS and EFS rates did not differ, irrespective of whether a chemotherapy-only based (n = 61) or a TBI-containing (n = 49) regimen were used. In contrast, for patients with RD, use of TBI-containing conditioning (n = 14) resulted in improved OS and EFS rates as compared with regimens based on chemotherapy alone (n = 19). Despite the small number of patients, the levels of significance for superiority of the TBI group were almost reached for OS (P = 0.061) and EFS (P = 0.070), and corresponding 95% confidence interval did not overlap at all (cf. Figures 2a and b) . Thus, univariate statistics support the results of our multivariate analysis that-beside the disease status in general-the use of TBI-containing conditioning in treatment refractory patients has an impact on HCT outcome. . The cutoff point ( o55 years) for patient age was selected according to the definition of patients regarded to be 'elderly' in numerous clinical studies. In contrast, the cutoff point for donor age ⩽ 42 years was identified to be the best discriminator for the clinical outcome of HCT. . Overall survival (OS, a) and event-free survival (EFS, b) after HCT for study patients surviving to day 100 post HCT according to the occurrence (yes/no) of limited chronic GvHD. OS and EFS data for patients without and with extended chronic GvHD were compiled as they did not differ according to log-rank test (Kaplan-Meier plots and corresponding 95% confidence intervals, for details see text).
As the results for TBI represent a subset analysis of a very limited number of patients, the authors cannot formally recommend the use of TBI-based conditioning in patients with RD. However, the possible benefits of TBI for patients with chemorefractory disease at the time of HCT are at hand: (1) FL is a radiosensitive entity, 42, 43 (2) TBI employs different death signal pathways than chemotherapy; and (3) TBI can reach inadequately perfused tissues as well as the subarachnoid space without limitations. [44] [45] [46] Interestingly, two large retrospective analyses 21, 47 provided evidence for superiority of TBI-based conditioning compared with chemotherapy-only based conditioning in FL patients in multivariate analyses. Moreover, a recently published trial from the EBMT Working Party also support superiority of TBI-based conditioning for FL patients in the autologous setting. 48 The third identified independent risk factor for HCT outcome is the occurrence of limited chronic GvHD.
With the exception of the small subgroup of patients (n = 14) with RD who received TBI-containing conditioning, the contribution of the conditioning regimen to cure FL appears to be modest for two reasons: (1) all study patients were intensively pretreated, including 90/146 patients who received an autologous HCT before allogeneic HCT; and (2) neither uni-nor multivariate statistical analysis could demonstrate a superior EFS for the subgroup of the 39 study patients treated with MAC.
Our data suggest that the potential of HCT to cure FL relies much more on the so-called GvL effect than on conditioning.
It is well established that transplanted donor immune cells can react against healthy as well as residual malignant cells of the recipient. 49, 50 Both reactions are guided by a common immunological mechanism, named allo-reactivity. Thus, the occurrence of GvHD is correlated with the GvL effect, as evidenced by numerous clinical studies. On the other hand-in contrast to limited chronic GvHD-extended chronic GvHD often is a life-threatening disease. These two facts explain why patients with limited chronic GvHD show better OS and EFS rates than patients without chronic GvHD or patients with extended chronic GvHD (cf. Table 2 , Figures 5a  and b) . The presence of chronic GvHD, irrespective of stage, was found to be correlated with a lower risk of relapse/a higher chance to achieve CR, whereas extended in contrast to limited chronic GvHD correlated with an increment of NRM, affecting OS and EFS rates.
Once established, the GvL effect might contribute to cure. The vast majority of the documented relapses (88%) occurred within the first 3 years after HCT in accordance with previously published studies, 23, 40 whereas only 2 of the 77 patients with a follow-up 45 years had a late relapse.
The final items to be discussed are the impact of patient and donor age on HCT outcome. As observed in numerous previous studies, 23, [51] [52] [53] [54] [55] [56] OS was found to be slightly lower in patients ⩾ 55 years without reaching any statistical significance in uni-and multivariate analysis. However, of greater clinical interest is that (1) the documented difference was so small that neither univariate nor multivariate analysis could reveal a significant impact of patient age on OS; and (2) stable plateaus for OS were reached for both subgroups, suggesting potential cure rates of 50% for younger and 42% for elderly patients (cf. Figure 4a ). These promising results for elderly patients can be easily explained. The vast majority of elderly patients were not treated with MAC known to be associated with an increased NRM risk. Furthermore, the beneficial action of the GvL effect is not limited by recipient age as it is mediated by the donor immune system.
The results of univariate analysis on donor age were clear-cut (cf. Figure 4b ): usage of a donor aged ⩽ 42 years is associated with significantly better OS after HCT (P = 0.0088). Numerous clinical studies focusing on other entities support the use of young donors. [57] [58] [59] [60] This finding remains valid even if multivariate analysis could not confirm donor age as an independent risk factor for HCT outcome. Donor age could not figure as a further independent risk factor, as young donor age was found to be linked with the established risk factor of limited chronic GvHD (U-test: P = 0.06).
Interestingly, in contrast to published studies in FL patients, [61] [62] [63] preceding autologous HCT included as a variable in uni-and multivariate statistical analysis could not be identified as a risk factor for inferior outcome after allogeneic HCT. In summary, this study demonstrates that a substantial number of patients with non-transformed FL have a realistic chance of cure, 64 even if presenting with RD state and/or advanced age (⩾ 55 years), and suggests that (1) patients with RD and/or Abbreviations: CI = confidence interval; EFS = event-free survival; HCT = hematopoietic cell transplantation; HR = hazard ratio; OS = overall survival. a Final model: independent risk factors for OS and EFS after testing the influence of all baseline variables depicted in Table 1. b Final model: independent risk factors for OS and EFS after testing the influence of all baseline variables plus the outcome variable occurrence of limited chronic GvHD (yes/no) for patients surviving day +100 after HCT. Allogeneic transplant may cure follicular lymphoma F Heinzelmann et al advanced age are candidates for HCT; (2) donors aged ⩽42 years are preferred; and (3) TBI-containing conditioning regimen might be a good option in patients with RD. Whether novel drugs such as PI3 kinase inhibitors 14 and bcl-2 inhibitors 16 or chimeric Ag receptor-enhanced T cells (CAR T cells) 17 -either alone or in combination-will finally erase or reduce the present role of allogeneic HCT in FL remains speculative today and has to be evaluated by future clinical studies.
